PCM
TXG icon

Prelude Capital Management’s 10x Genomics TXG Stock Holding History

Prelude Capital Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.01M Sell
78,597
-54,441
-41% -$1.43M 0.22% 112
2026
Q1 		$2.82M Buy
133,038
+41,055
+45% +$821K 0.22% 112
2025
Q4 		$1.5M Buy
91,983
+17,745
+24% +$268K 0.11% 202
2025
Q3 		$868K Buy
74,238
+21,169
+40% +$276K 0.07% 339
2025
Q2 		$615K Buy
+53,069
New +$484K 0.06% 384
2024
Q2 		– Sell
-5,753
Closed -$216K – 1502
2024
Q1 		$216K Buy
+5,753
New +$253K 0.01% 1071
2021
Q4 		– Sell
-1,386
Closed -$202K – 2258
2021
Q3 		$202K Sell
1,386
-1,622
-54% -$278K 0.01% 1362
2021
Q2 		$589K Buy
3,008
+642
+27% +$116K 0.02% 863
2021
Q1 		$428K Sell
2,366
-317
-12% -$54.7K 0.01% 973
2020
Q4 		$380K Buy
2,683
+494
+23% +$71.7K 0.01% 824
2020
Q3 		$273K Buy
2,189
+1,239
+130% +$130K 0.01% 594
2020
Q2 		$85K Buy
+950
New +$74K ﹤0.01% 1004

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Prelude Capital Management's TXG Position: Q2 2026 in Review

Prelude Capital Management reduced its 10x Genomics (TXG) stake by 41% in Q2 2026, selling an estimated $1.43M and leaving 78,597 shares worth $3.01M. The position accounts for 0.22% of the portfolio, ranked #112.

Prelude Capital Management first reported a position in TXG in Q2 2020 and has held it in 12 quarters since. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Prelude Capital Management held 78,597 shares of 10x Genomics worth $3.01M as of Q2 2026.
  • Prelude Capital Management sold 54,441 10x Genomics shares in Q2 2026, an estimated $1.43M.
  • 10x Genomics made up 0.22% of Prelude Capital Management's portfolio in Q2 2026, its #112 holding.
  • Prelude Capital Management first reported a position in 10x Genomics in Q2 2020 and has held it in 12 quarters since.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.